Search
Hydroxyzine
go.drugbank.com/drugs/DB00557ApprovedInvestigational[A189753] Hydroxyzine is also used for generalized anxiety disorder, tension caused by psychoneurosis, and other conditions with manifestations of anxiety.[L9677] … [L9677] The active metabolite of hydroxyzine, [cetirizine], is also available as an active ingredient in allergic medications, and is responsible for much of its hydroxyzine's antihistaminic effect.
Brexucabtagene autoleucel
go.drugbank.com/drugs/DB15699ApprovedInvestigational[L15148] Brexucabtagene autoleucel was granted full approval by the FDA on July 24, 2020 for the treatment of MCL and acute lymphoblastic leukemia (ALL), and is currently available through Kite Pharma … [A216153, A216158] More recently, chimeric antigen receptor (CAR) T cell therapies have been developed that modify a patient's own T cells using viral transduction to bind to and destroy cancerous cells
Categories: Receptors, Antigen, T-Cell, CD19-Directed Genetically Modified Autologous T-cell ImmunotherapiesCholic Acid
go.drugbank.com/drugs/DB02659ApprovedInvestigational[PubChem] Cholic acid, formulated as Cholbam capsules, is approved by the United States Food and Drug Administration as a treatment for children and adults with bile acid synthesis disorders due to single … enzyme defects, and for peroxisomal disorders (such as Zellweger syndrome).
Doxecitine
go.drugbank.com/drugs/DB02594ApprovedInvestigationalIt is an essential component of the deoxyribonucleotide pool required for DNA synthesis and repair. … This combination is the first and only approved treatment for Thymidine Kinase 2 deficiency.[L54613, L54618]
Bromodiphenhydramine
go.drugbank.com/drugs/DB01237ApprovedBromodiphenhydramine is an ethanolamine antihistamine with antimicrobial property. Bromodiphenhydramine is used in the control of cutaneous allergies. Ethanolamine antihistamines produce marked sedation in most patients.
Categories: Antihistamines for Systemic UsePrucalopride
go.drugbank.com/drugs/DB06480ApprovedInvestigational[A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880] … [A37348] The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies.
Categories: Drugs for ConstipationDigoxin
go.drugbank.com/drugs/DB00390ApprovedInvestigationalThey were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s.[A178240] … [A178237,A178240] Prior to this, a Welsh family, historically referred to as the _Physicians of Myddvai_, formulated drugs from this plant.
Categories: Compounds used in a research, industrial, or household settingProducts: DIGOXINA POR 0.25MG CAPSULAS BLANDASSodium Depletion
go.drugbank.com/conditions/DBCOND0093130Drugs: Sodium chlorideSynonyms: Low salt syndrome, Syndrome low saltAgomelatine
go.drugbank.com/drugs/DB06594ApprovedInvestigationalIn 2006 Servier sold the rights to develop Agomelatine in the US to Novartis. The development for the US market was discontinued in October 2011. … Agomelatine was developed in Europe by Servier Laboratories Ltd. and submitted to the European Medicines Agency (EMA) in 2005.
Fluvastatin
go.drugbank.com/drugs/DB01095ApprovedInvestigationalFluvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. … HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis.
Categories: Hypolipidemic Agents Indicated for Hyperlipidemia